Items where authors include "Ralph, C"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Rudin, CM, Pandha, HS, Zibelman, M et al. (18 more authors) (2023) Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 11 (1). e005007. ISSN 2051-1426

Samson, A orcid.org/0000-0002-3081-7850, West, EJ orcid.org/0000-0001-7449-120X, Carmichael, J et al. (27 more authors) (2022) Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 10 (6). pp. 745-756. ISSN 2326-6066

West, EJ, Scott, KJ, Tidswell, E et al. (11 more authors) (2022) Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers, 14 (9). 2181. ISSN 2072-6694

Zhong, J orcid.org/0000-0001-5325-3739, Palkhi, E, Buckley, DL orcid.org/0000-0001-6659-8365 et al. (7 more authors) (2021) Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 11 (7). 1302. ISSN 2075-4418

Müller, LME, Migneco, G, Scott, GB et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426

Hall, PE, Shepherd, STC, Brown, J et al. (19 more authors) (2020) Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 6 (5). P999-P1005. ISSN 2405-4569

Cheeseman, S, Thompson, M, Sopwith, W et al. (18 more authors) (2020) Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre. Frontiers in Oncology, 10. 167.

Mateo, J, Porta, N, Bianchini, D et al. (38 more authors) (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 21 (1). pp. 162-174. ISSN 1470-2045

Müller, LME, Holmes, M, Michael, JL et al. (20 more authors) (2019) Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for ImmunoTherapy of Cancer, 7. 164. ISSN 2051-1426

Zhong, J, Bambrook, J, Bhambra, B et al. (6 more authors) (2018) Incidence of Post-ablation Syndrome Following Image-Guided Percutaneous Cryoablation of Renal Cell Carcinoma: A Prospective Study. CardioVascular and Interventional Radiology, 41 (2). pp. 270-276. ISSN 0174-1551

Samson, A orcid.org/0000-0002-3081-7850, Scott, KJ orcid.org/0000-0002-5790-9579, Taggart, D et al. (36 more authors) (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 10 (422). eaam7577. ISSN 1946-6234

Colomba, E, Teuff, GL, Eisen, T et al. (28 more authors) (2017) Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European Journal of Cancer, 80. pp. 55-62. ISSN 0959-8049

Ilett, E, Kottke, T, Thompson, J et al. (12 more authors) (2017) Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumor therapy. Gene Therapy, 24 (1). pp. 21-30. ISSN 0969-7128

Powles, T, Lackner, MR, Oudard, S et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 34 (14). pp. 1660-1668. ISSN 0732-183X

Powles, T, Brown, J, Larkin, J et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Gravis, G, Chanez, B, Derosa, L et al. (19 more authors) (2016) Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 34 (4). 167.e17-167.e23. ISSN 1873-2496

Powles, T, Wheater, M, Din, O et al. (11 more authors) (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology, 69 (3). pp. 450-456. ISSN 0302-2838

Turnbull, S, West, EJ, Scott, KJ et al. (3 more authors) (2015) Evidence for oncolytic virotherapy: Where have we got to and where are we going? Viruses, 7 (12). pp. 6291-6312. ISSN 1999-4915

Mateo, J, Carreira, S, Sandhu, S et al. (48 more authors) (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 373 (18). pp. 1697-1708. ISSN 0028-4793

Conference or Workshop Item

Jones, RJ, Bahl, A, De Bono, JS et al. (17 more authors) (2021) SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group. In: 2021 Genitourinary Cancers Symposium, 11-13 Feb 2021, Online.

Anthoney, A, Samson, A orcid.org/0000-0002-3081-7850, West, E et al. (14 more authors) (2018) Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, Il, USA.

Proceedings Paper

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Ralph, C et al. (17 more authors) (2021) STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Paris, France. Elsevier , S1303-S1304.

Samson, A orcid.org/0000-0002-3081-7850, West, E, Turnbull, S et al. (13 more authors) (2019) 1213P: Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: Abstract Book of the 44th ESMO Congress. European Society for Medical Oncology (ESMO) 2019 Congress, 27 Sep - 01 Oct 2019, Barcelona, Spain. Oxford University Press , v475-v532.

Turnbull, S, West, E, Scott, K orcid.org/0000-0002-5790-9579 et al. (5 more authors) (2017) Revealing potential immune responses (IRs) in patients with advanced colorectal cancer (aCRC) on first line chemotherapy: A prospective study of neutrophil to lymphocyte ratio, immune function and outcome. In: Annals of Oncology. ESMO 2017 Congress, 08-12 Sep 2017, Madrid, Spain. Oxford University Press .

Sandhu, S, Mateo, J, Miranda, S et al. (31 more authors) (2015) Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial. In: Asia-Pacific Journal of Clinical Oncology. ANZUP Annual Scientific Meeting: Redefining Personalised Medicine, 12-14 Jul 2015, Sydney, Australia. Wiley , pp. 28-29.